Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare two drugs (nelfinavir [NFV] and efavirenz [EFV]) used in start-up anti-HIV treatment. Doctors want to see if one is better than the other in extending the time that viral load (level of HIV in the blood) is kept low. The study will also look at the response of the immune system to each drug.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Agouron Pharmaceuticals
• Treatments: Didanosine; Efavirenz; Keyhole-limpet hemocyanin; Lamivudine; Nelfinavir; Stavudine; Zidovudine

Criteria

Inclusion Criteria

Patients may be eligible for this trial if they:

• Are HIV-positive.

• Have a CD4 count of at least 100 cells/mm3.

• Have a viral load of at least 5,000 copies/ml.

Exclusion Criteria

Patients may not be eligible for this study if they:

• Have taken any antiretroviral (anti-HIV) agent.